Xanthones from the seeds of Allanblackia monticola and their apoptotic and antiproliferative activities.
Phytochemical investigations of the seeds of ALLANBLACKIA MONTICOLA have led to the isolation and characterization of one new xanthone derivative, named allanxanthone E ( 1), together with seven known compounds, including five xanthones, 1,7-dihydroxy-3-methoxy-2-(3-methylbut-2-enyl)xanthone ( 2), alpha-mangostin ( 3) , garciniafuran ( 4) , allanxanthone C ( 5), and 1,6-dihydroxy-2,4-diprenylxanthone ( 6), and two pentacyclic triterpenes, friedelin and lupeol. The structures of these compounds were established on the basis of one- and two-dimensional NMR homo- and heteronuclear correlation evidence. Some of these compounds were evaluated for their apoptotic and antiproliferative activities against human leukemic B lymphocytes, such as the hairy cell leukemia-derived ESKOL cell line and cells from B-CLL (B-cell chronic lymphocytic leukemia) patients.
Azebaze
Anatole Guy
AG
Department of Chemistry, Faculty of Science, University of Douala, Cameroon. azebaze@yahoo.com
Menasria
Faouzia
F
Noumi
Lylie Gwladys
LG
Nguemfo
Edwige Laure
EL
Tchamfo
Marie Fomani
MF
Nkengfack
Augustin Ephrem
AE
Kolb
Jean Pierre
JP
Meyer
Michèle
M
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival; D028084:Clusiaceae / Q000737:chemistry*; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D015394:Molecular Structure; D008517:Phytotherapy; D010936:Plant Extracts / Q000737:chemistry / Q000302:isolation & purification / Q000627:therapeutic use*; D012639:Seeds; D044004:Xanthones / Q000737:chemistry / Q000302:isolation & purification / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; D010936:Plant Extracts; D044004:Xanthones; C539812:allanxanthone E